Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Korea's Green Cross Wins Bid To Supply Chicken Pox Vaccine to WHO

This article was originally published in PharmAsia News

Executive Summary

SEOUL - South Korea's leading vaccine maker Green Cross has won another round of international bidding to supply the World Health Organization's Pan American Health Organization with its chicken pox vaccine Suduvax worth $10.4 million

You may also be interested in...



Green Cross Becomes First Korean Pharma To Export Flu Vaccine

SEOUL - South Korea's vaccine producer Green Cross shipped its first batch of flu vaccine GCFlu to the World Health Organization's Pan American Health Organization June 8 in accordance with a $6 million deal signed in March.Noting that it is the first Korean pharma to export seasonal flu vaccine, Green Cross said it is to make the second and third shipments of the vaccine by the end of June

Green Cross Becomes First Korean Pharma To Export Flu Vaccine

SEOUL - South Korea's vaccine producer Green Cross shipped its first batch of flu vaccine GCFlu to the World Health Organization's Pan American Health Organization June 8 in accordance with a $6 million deal signed in March.Noting that it is the first Korean pharma to export seasonal flu vaccine, Green Cross said it is to make the second and third shipments of the vaccine by the end of June

Demand For A/H1N1 Vaccine Catapults Green Cross Into No. 2 Spot In Korea; Company Ramps Up Biosimilar Pipeline

SEOUL - Of the many local Korean pharmaceutical players, vaccine producer Green Cross was the biggest beneficiary of the A/H1N1 flu pandemic last year as increased demand for its vaccines triggered a remarkable upgrade in its rankings to the second-largest from its previous long-time position of No. 5

Related Content

UsernamePublicRestriction

Register

LL016481

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel